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Summary
Background—EGFR antibodies have been shown to increase survival in patients with advanced 
non-small cell lung cancer (NSCLC), particularly with squamous cell (SC) histology. Our prior 
work suggested that EGFR copy number by fluorescence in-situ hybridization (FISH) identifies 
patients most likely to benefit from these agents combined with chemotherapy. This study aimed 
to explore the activity of cetuximab with chemotherapy in EGFR-FISH positive (EGFR-FISH+) 
patients.
Methods—S0819 was a multicenter, open-label, Phase III study. Eligible patients with treatment-
naïve Stage IV NSCLC were randomized with equal probability to receive paclitaxel (200 mg/m2; 
q21d) plus carboplatin (AUC = 6; q21d) or carboplatin plus paclitaxel and bevacizumab (15 
mg/kg; q21d) with or without cetuximab (250 mg/m2 weekly after loading dose). Randomization 
was stratified by bevacizumab treatment, smoking status, and M-substage using a dynamic 
balancing algorithm. Co-primary objectives were progression-free survival (PFS) in patients with 
EGFR-FISH+ cancers and overall survival (OS) in the overall study population. Intention-to-treat 
analyses were employed for primary and secondary outcomes; the safety population included 
patients who received at least one dose of study drug. This completed study is registered with 
ClinicalTrials.gov (NCT00946712).
Findings—Between August 2009 and June 2014, 1,333 patients were enrolled and 1,313 patients 
were randomized (control group: 277/380 bevacizumab-treated [BT]/no bevacizumab [BN]; 
cetuximab group: 283/373 BT/BN). EGFR FISH was assessable in 976 patients; 400 (41%) were 
EGFR-FISH+. PFS was not significantly different between the arms among the EGFR-FISH+ 
subpopulation (HR=0·92 [0·75–1·12], P=0·40). OS was not significantly different among treatment 
arms in the overall study population (HR=0·93 [0·83–1·04], P=0·22). In a prespecified analysis 
among patients with EGFR-FISH+ cancers with SC histology, OS was significantly improved in 
the cetuximab group (HR=0·58 [0·39–0·86], P=0·01): median OS of 11·8 months (95% CI: 8·6–
13·5) and 6·1 months (95% CI: 4·2–8·7) in cetuximab and control arms, respectively. The most 
common grade 3–4 AEs were neutrophils (n=210 cetuximab; n=158 control), leukocytes (n=103 
cetuximab; n=74 control), fatigue (n=81 cetuximab; n=74 control) and rash (n=52 cetuximab; n=1 
control). Grade 5 AEs occurred in 5% (n=32) of cetuximab and 2% (n=13) of controls.
Interpretation—Although this study did not meet its primary endpoints, subgroup analyses of 
patients with EGFR-FISH+ cancers by histology suggests further study of cetuximab is warranted 
in those with SC cancers. These data, together with other recent trials, support continued 
evaluation of anti-EGFR antibodies in this subpopulation.
Funding—National Cancer Institute and Eli Lilly and Company
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Introduction
Though the incidence and mortality rates associated with lung cancer have steadily declined, 
lung cancer continues to be the leading cause of cancer death in the United States (US); over 
158,000 associated deaths were estimated for 2016.1 Non-small cell lung cancer (NSCLC) 
constitutes approximately 80% of lung cancers. The standard of care for advanced NSCLC 
has evolved, from best supportive care to the use of multiple regimens including platinum-
based chemotherapy, molecularly targeted agents, and immunotherapy.2 Of the targeted 
agents, those inhibiting the epidermal growth factor receptor (EGFR) have experienced 
multiple generations of development.3–6 The tyrosine kinase inhibitors (TKIs) erlotinib, 
gefitinib, and afatinib confer dramatic clinical responses in the subset of patients who harbor 
EGFR tyrosine kinase domain mutations, and have shown only modest efficacy in 
unselected previously-treated patients3, but have been less effective as first-line agents in 
combination with chemotherapy in EGFR unmutated patients with advanced NSCLC.7
Cetuximab, a highly specific, chimerized, monoclonal antibody targeting EGFR, has been 
investigated in combination with platinum-based chemotherapies for the treatment of 
chemotherapy-naïve patients with advanced NSCLC based upon biological evidence 
demonstrating the EGFR pathway plays a role in lung cancer development and progression.
8, 9 Furthermore, the lack of efficacy of oral EGFR TKIs in combination with chemotherapy 
suggested an alternative EGFR-directed approach was needed and preclinical models 
showed synergy with chemotherapy and cetuximab.5, 10, 11 Though in EGFR mutated 
patients using varied dosing schedules there were hints of activity for EGFR TKI and 
chemotherapy. SWOG conducted two Phase II clinical trials to evaluate the efficacy and 
safety of adding cetuximab to first-line treatment of advanced NSCLC – S0342 and 
S0536.12–14 The S0342 trial evaluated if there was sufficient activity of cetuximab 
concurrently with or sequentially after chemotherapy in treatment-naïve advanced NSCLC 
in order to select one of these regimens for further study.12 A secondary analysis of this trial 
indicated that EGFR copy number, as assessed by fluorescence in situ hybridization (EGFR 
FISH), may be associated with improved survival in this patient population.13 The S0536 
trial was designed to assess the safety and feasibility of a chemotherapy doublet 
(carboplatin/paclitaxel) given concurrently with a biologic doublet consisting of the anti-
vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and 
cetuximab as first-line therapy in advanced NSCLC.14 This trial also assessed EGFR FISH 
as a biomarker of response. The primary safety endpoint evaluating Grade 4–5 hemorrhage-
related toxicities was met, with only 2% (n = 2) of the study population experiencing Grade 
5 pulmonary hemorrhage, with all other toxicities similar to previous cetuximab 
combinations.12, 14, 15 The overall response rate (RR) was 56% (52 of 95 patients) and the 
overall disease control rate was 77%; moreover, the median PFS was 7 months and OS was 
15 months.14 The results supported a potential relationship between EGFR FISH-positivity 
and enhanced clinical outcome.14
Given the overall safety, efficacy, and biomarker results from the S0342 and S0536 studies, 
this Phase III biomarker validation study investigated the safety and effectiveness of first-
line therapy with cetuximab plus carboplatin/paclitaxel chemotherapy with or without 
bevacizumab in patients with advanced NSCLC and was designed to validate EGFR FISH as 
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a predictive biomarker for cetuximab in this population.16 We hypothesized that EGFR 
FISH-positivity would be associated with increased PFS and/or OS.
Methods
Study design and participants
This was a randomized, multicenter, Phase III study of carboplatin plus paclitaxel or 
carboplatin plus paclitaxel and bevacizumab with or without cetuximab in patients with 
advanced NSCLC (list of centers in Appendix page 1). Patients had histologically/
cytologically proven Stage IV primary NSCLC that was newly diagnosed or recurrent after 
previous surgery and/or irradiation. Patients were excluded if they received prior 
chemotherapy for NSCLC, platinum-based chemotherapy for any purpose, any drug 
targeting the EGFR or VEGF pathways, any chimerized or mouse monoclonal antibody 
therapies, or had documented presence of human anti-mouse antibodies. Patients were 
required to have CT or MRI scans to document the extent of their disease; measurable 
disease was assessed within 28 days prior to registration and non-measurable disease was 
assessed within 42 days of registration. CT or MRI scans were required within 42 days prior 
to registration in order to determine the extent of central nervous system disease; patients 
with adequately treated, controlled brain metastases were allowed if the patient had no 
residual neurological dysfunction off corticosteroids for ≥ 1 day. At least 28 days must have 
passed since major surgery was performed on patients. Laboratory and clinical tests were 
performed within 14 days prior to registration and results had to meet the following 
requirements: absolute neutrophil count ≥ 1,500/mcl; platelet count ≥ 100,000/mcl; 
hemoglobin ≥ 9 g/dL; serum creatinine ≤ the institutional upper limit of normal (IULN) and 
a calculated or measured creatinine clearance ≥ 50 cc/min; adequate hepatic function (serum 
bilirubin ≤ 2x IULN and either SGOT or SGPT ≤ 2x IULN; for patients with liver 
metastases, bilirubin and either SGOT or SGPT must be ≤ 5x IULN); Zubrod performance 
status of 0 (fully active, able to carry on all pre-disease performance without restriction) to 1 
(restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature); < Grade 2 symptomatic neuropathy-sensory; no evidence of active 
infection or acute hepatitis; no history (within the prior 6 months) of cerebrovascular 
accident, myocardial infarction or unstable angina and no evidence of uncontrolled 
hypertension, NYHA Grade 2 or higher congestive heart failure, serious cardiac arrhythmia 
requiring medication or clinically significant vascular disease. No other prior malignancy 
was allowed except adequately treated basal cell or squamous cell (SC) skin cancer, in situ 
cervical cancers, adequately treated Stage I or II cancer from which the patient is in 
complete remission, or any other cancer from which the patient has been disease-free for 5 
years. Patients provided prior smoking history and were prohibited from becoming pregnant 
or nursing due to the increased risk of fetal harm from the chemotherapeutic agents.
Patients were bevacizumab inappropriate if they had any of the following: ≥ 50% SC tumor 
component; history of hemoptysis (≥ ½ tsp per event within the past year); cavitary 
pulmonary lesion; history of documented hemorrhagic diathesis or coagulopathy; non-
healing wound, or bone fracture, abdominal fistula, gastrointestinal perforation or intra-
abdominal abscess; patients receiving anticoagulation. Patients were placed in the 
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“bevacizumab no” (BN) stratum if they did not receive bevacizumab; reasons could include 
being bevacizumab inappropriate or if the patient or physician decided to not treat the 
patient with bevacizumab. Patients with central nervous system metastases were defined as 
bevacizumab appropriate until protocol amendment in June 2013. For patients receiving 
bevacizumab, if urine protein creatinine ratio was > 0.5, 24-hour urine protein was required 
to be < 1,000 mg for enrollment. The S0819 trial (Trial Registry: ClinicalTrials.gov 
Identifier: NCT00946712) was approved by the institutional review boards of the 
participating institutions and all patients provided informed consent.
Randomization
Patients were randomized with equal probability. The study was open label. Randomization 
was stratified by bevacizumab treatment status (having received bevacizumab treatment [BT] 
versus BN), smoking status (current or former versus never), and stage (M1a versus M1b) 
using a dynamic balancing algorithm.17 Patients were enrolled via a web-based application 
and simultaneously randomized by a computer program. Sites were automatically notified of 
the patient’s randomization arm at the time of enrollment.
Procedures
Patients received chemotherapy with paclitaxel (200 mg/m2; 3 hour IV infusion; q21d) and 
carboplatin (AUC = 6 by modified Calvert formula; 30 minute IV infusion immediately 
following paclitaxel; q21d) for a maximum of 6 cycles or until one of the criteria for 
removal from treatment was met, which included disease progression based on investigator’s 
assessment or symptomatic deterioration, unacceptable toxicity, or treatment delay > 4 
weeks. Carboplatin and paclitaxel were chosen as the chemotherapy regimen for this trial 
because this regimen was acceptable for all histologies that were eligible for the trial, and 
because of prior SWOG data with this regimen in combination in the Phase II S0342 trial.
For the patients receiving bevacizumab (15 mg/kg; 30–90 minute IV infusion occurred 1 
hour following carboplatin; q21d). The patients randomized to cetuximab received 400 
mg/m2 loading dose as a 2-hour IV infusion on Week 1 of Cycle 1, followed by 250 mg/m2 
weekly dosing starting on Week 2, one hour prior to paclitaxel. Patients randomized to 
receive cetuximab were pre-medicated with 50 mg IV diphenhydramine hydrochloride prior 
to the first dose of cetuximab to prevent hypersensitivity reaction. Dose reductions were 
allowed in the event of toxicity and all dose reductions were permanent. Laboratory 
monitoring occurred every cycle of treatment starting at Cycle 2 and included complete 
blood counts, serum creatinine, calculated or measured creatinine clearance, urine protein 
creatinine ratio, total bilirubin, serum glutamic oxaloacetic transaminase or serum glutamic 
aspartate aminotransferase, alkaline phosphatase, international normalized ratio, albumin, 
lactate dehydrogenase serum sodium, calcium, and magnesium. Assessment of toxicity was 
done by CTCAE 4.0 and was performed at every cycle of treatment starting at Cycle 2.
Patients were followed for 3 years after registration or until death. CT or MRI scans were 
ascertained every 6 weeks for the first 9 months and every 3 months thereafter, until disease 
progression.
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Paraffin-embedded, formalin fixed tumor specimens or fine needle aspirate slides were 
submitted prior to the start of therapy for EGFR FISH analysis. EGFR FISH and KRAS 
mutational status were evaluated at each interim analysis.
EGFR FISH analysis was performed using the “Colorado EGFR Scoring System,” as 
reported.13 Tumors were considered to be EGFR FISH-positive (EGFR-FISH+) if they 
harbored four or more copies of EGFR in ≥ 40% of cells or if they showed EGFR 
amplification (defined as gene-to-chromosome ratio ≥ 2 or presence of gene cluster or ≥ 15 
gene copies in ≥ 10% of cells). Tumors that were successfully tested and failed to meet these 
criteria were classified as EGFR FISH-negative. EGFR mutational testing was not a required 
test for this trial.
Outcomes
The primary co-objectives were to compare PFS by institutional review in EGFR-FISH+ 
patients and OS in the entire study population. Central review of PFS was specified in the 
protocol, however, this data will be presented in a separate manuscript. Secondary objectives 
included comparison of OS in EGFR-FISH+ patients; comparison of PFS in the entire study 
population, comparison of response rates (confirmed plus unconfirmed, complete and partial 
responses) by RECIST 1.1 in the subset of patients with measurable disease in the entire 
study population and the EGFR-FISH+ subset; assessment of the toxicity by CTCAE 4.0 of 
each treatment arm and by BN or BT subgroups; prospective testing of EGFR FISH as a 
predictive marker for the selection of patients for cetuximab plus chemotherapy; a 
comparison of OS and PFS within the BT and BN subgroups; an evaluation of the role of 
KRAS mutations in terms of cetuximab efficacy; and comparison of results of EGFR FISH 
with KRAS mutations, EGFR mutations, EGFR immunohistochemistry (IHC), and other 
purported EGFR-related biomarkers. The analysis of KRAS, EGFR IHC, and other EGFR-
related biomarkers will be presented in a separate manuscript.
Statistical analysis
The basis for the statistical design of the study has been previously described.16 OS was 
defined as the duration from registration to death due to any cause. Patients last known to be 
alive were censored at the date of last contact. PFS was defined as the duration from 
randomization to progression, symptomatic deterioration, or death due to any cause 
(whichever comes first), by RECIST 1·1 as assessed by the treating investigator. Patients last 
known to be alive and progression free were censored at the date of last contact. The primary 
analysis was by intention to treat.
While the study employs co-primary objectives, the sample size was based on the primary 
objective within the EGFR-FISH+ population. The study-wide type I error is 2·5%, with 2% 
allocated to the EGFR-FISH+ objective. The original design for the EGFR-FISH+ objective 
was based on the following specifications: a design with 92% power to detect a hazard ratio 
(HR) of 0·75 at the 1-sided 2% level requires 297 PFS events. Then, assuming exponential 
survival, 50% of patients are BT, a median PFS of 4 months among BN patients, a median 
PFS of 6 months in BT patients, uniform accrual over 4 years, and 1 year of follow-up, 618 
EGFR-FISH+ patients are needed.
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The total target sample size was 1,546 patients, which was based on the assumption that 
80% of patients would be evaluable for EGFR FISH status, and of them, 50% would be 
EGFR-FISH+. The level of testing within the entire study population was set to be 0·015, 
accounting for the correlation between the two co-primary objectives. Under the design 
assumptions above, and assuming a median OS of 10 and 12 months within BN and BT 
patients respectively, the study had 86% power to detect a HR of 0·83 for OS using a 1-sided 
0·015 level log-rank test within the entire study population. As the sample size for the study 
was determined by the number of EGFR-FISH+ patients accrued, the study protocol 
included specification that the study may be modified based on the observed prevalence of 
EGFR FISH-positivity.
As discussed in the results section, the observed prevalence of EGFR FISH-positivity was 
41% and the percentage of patients with known EGFR FISH status was lower than specified 
(74% with known FISH status). On June 1st, 2014, the study design was amended to account 
for the lower than estimated percentage of accrued patients known to be EGFR-FISH+. The 
accrual rate to the study was also lower than anticipated. The amended accrual goal was 400 
EGFR-FISH+ patients; based on a design with 80% power, all other design parameters 
remained unchanged.
The interim analysis plan is fully described in Redman et al.16 Interim analyses were to take 
place when 30%, 67%, and 85% of the expected PFS within the EGFR-FISH+ population 
were observed. Interim analyses evaluated early stopping for either efficacy or futility both 
in the overall population and by FISH grouping.
OS and PFS were analyzed using a two-sided log-rank test stratified according to the factors 
listed above. HRs and corresponding confidence intervals (CIs) were estimated using a 
stratified Cox proportional-hazards model, with randomized group as a single covariate. The 
proportional hazards assumption was not evaluated. Survival curves for each treatment 
group were estimated by Kaplan–Meier method. Survival rates were derived from the 
Kaplan–Meier estimates. ORRs were compared using a two-sided, stratified Cochran–
Mantel–Haenszel test, with exact 95% CIs calculated with the use of the Clopper–Pearson 
method. SAS (version 9.4) was used for all statistical analyses. Secondary analyses used a 
significance level of 5%. Analysis of clinical outcomes employed the intention-to-treat 
principle including all randomized patients excluding those found ineligible centrally after 
randomization. Analysis of toxicity included patients who received at least one dose of 
protocol treatment. The study was overseen by the SWOG Data Safety Monitoring 
Committee (DSMC) on a twice a year basis.
Role of the funding source
This trial was sponsored by SWOG/NCI cooperative group of which the authors are 
members. The funder contributed to study design, data collection, data analysis, data 
interpretation, and writing of the report. The corresponding author had full access to all of 
the data in the study and had final responsibility for the decision to submit for publication.
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Results
From August 13, 2009 to May 30, 2014, 1,333 patients were enrolled in the trial; 20 were 
deemed ineligible, resulting in 1,313 patients in the eligible study population: chemotherapy 
plus cetuximab arm (n = 656) and the chemotherapy without cetuximab arm (control) (n = 
657) (Figure 1). The median follow-up duration for patients last known to be alive is 35.2 
months with a range of 0.3–60 months and interquartile range of 22.9–39.9 months. Patient 
demographics and characteristics by treatment group are described in Table 1. Specimens for 
EGFR FISH testing were evaluated in 1,190 (91%) of the 1,313 eligible patients. Specimens 
from 1,034 patients (87%) were adequate for testing. The FISH assay failed in specimens 
from 58 patients leaving 976 patients (94%) with assessable specimens. Of these 976 
specimens, 400 (41%) were EGFR-FISH+. The remaining 913 eligible patients are classified 
as FISH non-positive (combination of EGFR negative and EGFR status unknown).
Of 1,313 patients eligible for treatment, 53 did not receive any protocol treatment and one 
patient withdrew consent prior to being evaluated for toxicity; the resulting 1,259 patients 
(627 in the cetuximab arm and 632 in the control group) were evaluated for safety events. 
Major protocol deviations occurred in 136 patients (some had more than one deviation): in 
addition to the 53 patients who did not receive treatment, 51 were deemed BN but treated 
with bevacizumab, 23 experienced a carboplatin dosing error, and 16 others were considered 
protocol deviations for miscellaneous reasons.
Results of the primary, secondary, and subgroup analyses are presented in Figures 2 and 3. 
The first co-primary objective was a comparison of PFS between the treatment arms in 
patients with EGFR-FISH+ cancers. In patients with EGFR-FISH+ cancers, the distribution 
of PFS was not significantly different between the treatment arms (HR = 0·92 [0·75–1·12], P 
= 0·40). The median PFS was 4·8 months (95% CI: 3·9–5·5) in the control arm and 5·4 
months (95% CI: 4·5–5·7) in the cetuximab-containing arm (Table 2). However, OS was 
significantly different between the arms (HR = 0·81 [0·66–1·0], P = 0·048). The median OS 
was 9·8 months (95% CI: 8·7–12·1) in the control arm and 13·4 months (95% CI: 11·5–14·8) 
in cetuximab-containing arm. RRs in the patients with EGFR-FISH+ cancers were not 
significantly different between the arms (43% control arm versus 47% cetuximab-containing 
arm, P = 0·48).
The second co-primary objective was a comparison of OS between the cetuximab-containing 
and control arms within the entire study population. There was no difference in the survival 
distribution between the arms (HR = 0·93 [0·83–1·04], P = 0·22). The median OS was 9·2 
months (95% CI: 8·7–10·3) in the control arm and 10·9 months (95% CI: 9·5–12·0) in the 
cetuximab-containing arm (Table 2). In addition, PFS was not different between the arms 
(HR = 0·99 [0·88–1·10], P = 0·83). The median PFS was 4·5 months (95% CI: 4·2–5·1) in 
the control arm and 4.6 months (95% CI: 4·2–5·2) in cetuximab-containing arm. RRs were 
not significantly different between the arms (36% control arm versus 42% cetuximab-
containing arm, P = 0·06)
Secondary objectives included a comparison of treatment arm outcomes within the BT and 
BN subsets. These analyses are summarized in Figure 2. In BT patients, there was no 
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difference in OS (P = 0·72) or PFS (P = 0·62) between the arms. In addition, among BT 
patients with EGFR-FISH+ cancers, there was no difference in OS (P = 0·43) or PFS (P = 
0·74) between the arms. Among BN patients, there was no statistically significant difference 
in OS (P = 0·19) or PFS (P = 0·49) between the arms. In addition, among the subpopulation 
of BN patients with EGFR-FISH+ cancers, the difference in OS between the arms was non-
significant (P = 0·07) and the difference in PFS between the arms was not statistically 
significant (P = 0·16).
Prior to analysis of the data, the study team added a pre-specified analysis of OS or PFS and 
treatment among patients with SC histology, both overall and stratified by EGFR FISH 
status based on results from the SQUIRE trial.18 In the subpopulation of patients with SC 
histology, there was no difference in OS (P = 0·17), PFS (P = 0·29) or RR (35% versus 39%, 
P = 0·42) between the treatment arms. However, among the EGFR-FISH+ subpopulation 
with SC histology, OS was significantly improved in the cetuximab-containing arm 
compared with the control arm (P = 0·01) with a median OS of 6·1 months (95% CI: 4·2–
8·7) in the control arm and 11·8 months (95% CI: 8·6–13·5) in the cetuximab-containing 
arm. There was not a significant difference in PFS between the arms in this subgroup (P = 
0·06) and the respective medians were 2·8 (95% CI: 2·6–4·1) and 4·5 (95% CI: 3·8–5·2) for 
the control arm and the cetuximab-containing arm. RRs were not significantly different 
between treatment arms among the EGFR-FISH+ subpopulation with SC histology (P = 
0·46). RRs were not significantly different between the treatment arms stratified by SC and 
non-SC histology (SC: P = 0·42 and non-SC: P = 0·09). In addition, RRs were not 
significantly different between treatment arms among the EGFR-FISH+ subpopulation with 
non-SC histology (P = 0·72). The HRs and associated CIs from all of the primary and sub-
group analyses are graphically summarized in forest plots in Figure 3. Response rates from 
the overall population and sub-group analyses and associated statistics are summarized in 
Table 3.
Grade 5 adverse events were higher in the cetuximab-containing arm (4·4% BN and 6·0% 
BT) compared to the control arm (2·5% BN and 1·5% BT). Grade 3/4 adverse events 
occurred more frequently in the BT group (76·3% cetuximab BT and 67·4% control BT 
group) compared to patients who did not receive bevacizumab (66·5% cetuximab BN and 
55·6% control BN group) (Table 4). As expected, 90% of patients with cetuximab 
experienced some sort of skin rash. Forty-three percent of patients who progressed on the 
control arm (254/594), and 44% (257/590) on the cetuximab arm reported receiving therapy 
after progression on this study. Post-progression therapy appears to be balanced between the 
arms.
In the control arm, 593 patients died. There were 13 treatment-related deaths: four due to 
infection/febrile neutropenia, two due to lung hemorrhage, one due to dyspnea, one due to 
decreased carbon monoxide diffusing capacity (DLCO), one due to DLCO and respiratory 
failure, one due to respiratory failure, one due dyspnea, asystole, and cardiac arrest, one due 
to CNS ischemia and one for whom the exact cause of death could not be determined. An 
additional 10 patients died due to adverse events unrelated to treatment. These include: 
pneumonitis (n = 1), pulmonary disease (n = 3), cardiac disease (n = 2), infection (n = 1), 
perforation of the stomach (n = 1), DLCO (n = 1), aorta injury (n = 1), and thrombosis/
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embolism with cardiac disease (n = 1) (one death attributed to two adverse events). The 
remaining 570 deaths in this arm were due to disease progression.
In the cetuximab arm, 570 patients died. There were 32 treatment-related deaths: five due to 
infection, three due to hemorrhage, two due to perforation of the colon, two due to multi -
organ failure, two due to DLCO, one due to respiratory failure, one due to cardiac arrest, one 
due to seizure, one due to a pneumoperitoneum, one due to thrombosis/embolism, one due to 
thrombosis/embolism in combination with other unidentifiable causes, one due to 
hypotension, one due to dyspnea, one due to cytokine release syndrome, one due to CNS 
ischemia, and eight for whom the exact cause of death could not be determined. An 
additional 13 patients have died due to adverse events unrelated to treatment. These include: 
CNS ischemia with cardiac ischemia/infarction (n = 1), DLCO (n = 2), thrombosis/
embolism (n = 1), thrombotic microangiopathy (n = 1), dyspnea (n = 2), cardiac disease (n = 
1), pleural effusion (n = 2), lung hemorrhage (n = 1), pulmonary disease (n = 1), and 
aspiration (n = 1). The remaining 525 deaths were due to disease progression.
Severe adverse events (SAEs) were defined as all grade 5 and unexpected grade 4 adverse 
events related to treatment. The cetuximab arm had 59 (9%) patients experience SAEs with 
allergic reaction (n=8) and death (n=11) being the most common. The control arm had 31 
(5%) patients experience SAEs with pulmonary (n=6) and febrile neutropenia (n=5) being 
the most common. (Appendix page 6)
In terms of safety and tolerability, on the control arm, 632 patients received protocol 
treatment, with 262 (41%) having at least one dose reduction of one of the agents during the 
entire course of their protocol treatment. This included 142 (53%) of 267 patients receiving 
bevacizumab, and 120 (33%) of patients not receiving bevacizumab. Of the 627 patients who 
received protocol treatment on the cetuximab arm, 365 (58%) had at least one dose 
reduction of one of the agents during the entire course of their protocol treatment. This 
included 188 (71%) of 266 patients receiving bevacizumab, and 177 (49%) of patients not 
receiving bevacizumab. Patients who discontinued treated for drug-related toxicity are 
summarized in Figure 1, with detailed causes available in Appendix page 8.
Discussion
In this randomized, multicenter, Phase III trial, the addition of cetuximab to standard 
chemotherapy did not meet its co-primary objectives of prolonging PFS in the patients with 
EGFR-FISH+ cancers or OS in the entire population. The scientific premise of this study 
was based on the hypothesis, and prior preclinical/clinical data, that EGFR antibodies (as 
opposed to EGFR TKIs) synergize with chemotherapy, and that this synergy is enhanced in 
patients with EGFR-FISH+ cancers.5, 10, 11
The EGFR pathway plays a role in non-mutated NSCLC as evidenced by the small benefit 
of erlotinib versus placebo in the 2nd–3rd -line treatment setting.3 However, when EGFR 
TKIs were evaluated concurrently with chemotherapy in untreated patients, no clinical 
benefit was seen.7, 19.EGFR monoclonal antibodies represent alternatives for EGFR 
inhibition in non-mutated NSCLC due to additional effects on receptor internalization and 
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antibody-dependent cellular toxicity not seen with EGFR TKIs.20, 21 Indeed, cetuximab has 
produced favorable efficacy with platinum-based chemotherapy in early lung cancer studies 
and is well recognized for its activity in combination with chemotherapy and/or radiotherapy 
in other tumor types such as colorectal cancer and head and neck cancer.22 Cetuximab 
produced favorable efficacy with platinum-based chemotherapy in several early phase 
NSCLC studies.20 Two NSCLC Phase III trials investigating chemotherapy plus cetuximab 
revealed contradictory results: the FLEX trial met its primary OS endpoint, while the 
BMS-099 trial did not meet its primary PFS endpoint.8, 9 A meta-analysis of cetuximab 
trials in NSCLC concluded that the addition of cetuximab to a platinum doublet significantly 
improved RR, PFS, and OS with a manageable toxicity profile.23 Of additional interest, in 
the FLEX trial the greatest benefit in OS was achieved in those patients with SC histology 
cancers, especially those with high EGFR protein expression.24 While SC histology NSCLC 
rarely harbors EGFR mutation, it is known to have a high incidence of EGFR expression. 
Following this observation, a recently completed Phase III trial (SQUIRE) in advanced stage 
SC lung cancer of gemcitabine-cisplatin with or without the newer EGFR monoclonal 
antibody necitumumab also demonstrated improved OS, resulting in approval of this 
regimen in the US and Europe.18
The current trial, S0819, was the largest study conducted to definitively evaluate the role of 
cetuximab in patients with EGFR-FISH+ cancers and in unselected patients with advanced 
NSCLC. In the unselected patient population, OS was similar between the arms. The median 
OS and PFS were similar to those in the BMS-099 trial. These results may have been 
predictable given that no „all-comer’ frontline, randomized, Phase III trial of chemotherapy 
plus a targeted agent has shown a survival advantage with the exception of the modest 
survival benefit with bevacizumab plus paclitaxel and carboplatin demonstrated in the E4599 
trial.15 Building on this triplet therapy, S0536 sought to evaluate if the addition of cetuximab 
to the regimen would be safe and enhance efficacy.14 S0536 did indeed demonstrate a non-
overlapping and a manageable toxicity profile coupled with a numerically higher RR, PFS, 
and OS over the triplet therapy garnering further support for cetuximab as an active agent in 
lung cancer. However, our study did not show a survival benefit of the four-drug regimen. 
The highly selective patient population enrolled in S0536 may have accounted for the 
positive findings not confirmed in this larger randomized trial. In our study, a total of 554 
(41·5%) patients received chemotherapy and bevacizumab with or without cetuximab.
Success with targeted therapies in lung cancer is largely attributable to identifying a 
predictive biomarker; therefore, incorporating a biomarker-driven co-primary endpoint was 
essential to this study. As such, and to the best of our knowledge, S0819 is the first 
cooperative group, Phase III trial to utilize this strategy. EGFR FISH-positivity was selected 
as a promising predictive biomarker of outcome for the treatment of advanced NSCLC with 
EGFR inhibitors based on several trials.16, 25, 26 In the Canadian, Phase III BR·21 study 
comparing erlotinib with placebo in patients whose disease progressed despite 
chemotherapy, the authors found statistically significant associations between objective 
response and polysomy or amplification of EGFR.26 A similar result was ascertained from 
the Phase III FLEX study, which showed a significant benefit of cetuximab in addition to 
cisplatin/vinorelbine chemotherapy in extending survival in patients whose cancers exhibited 
high levels of EGFR.25 As mentioned earlier, EGFR FISH-positivity was associated with 
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significantly longer median OS and PFS in patients treated with cetuximab, carboplatin, and 
paclitaxel in S0342.13, 26–30
Tissue acquisition was critical for this study and efforts aimed at improving its quality were 
central to this protocol. Of all tissue specimens received, 91% were determined to be in 
usable condition, 87% were analyzable for EGFR FISH, and the assay was successful in 
94% of specimens. Specific efforts were made to improved rates of usable and analyzable 
tissue over the course of study. A separate manuscript is in development to describe these 
efforts and their impact.
Although EGFR FISH was not a predictive marker for the overall patient population in our 
study, we identified a subpopulation of patients with SC histology in which EGFR FISH-
positivity predicted a beneficial response to treatment with cetuximab. As previously stated, 
SC histology is known to have a high incidence of EGFR expression.28 In this select group 
of patients, the addition of cetuximab to chemotherapy improved OS (HR = 0·58 [0·39–
0·86], P = 0·01) over the control group. These results are very similar to those observed in 
the EGFR-FISH+ cohort in the SC SQUIRE trial using necitumumab with gemcitabine-
cisplatin (HR = 0·79 [0·69–0·92], P = 0·002 for OS and HR = 0·84 [0·72–0·97], P = 0·018 
for PFS versus gemcitabine-cisplatin without necitumumab) in which EGFR FISH was 
assessed by the same methodology in the same laboratory.18 These findings indicate a 
different predictive mechanism for EGFR monoclonal antibodies compared to EGFR TKIs 
that could be beneficial in distinct biological subsets.
Cetuximab treatment was associated with an increase in Grade 3/4 adverse events for acne/
rash and allergic reaction. However, the safety profile was similar to that reported in other 
Phase III trials of cetuximab treatment.8, 9 With respect to the quadruple drug combination, 
the addition of bevacizumab did increase cetuximab toxicity with regard to some events, 
including fatigue, acne/rash, thrombosis/embolism, hypertension, and myalgias. Future 
clinical trials investigating combinations with immune checkpoint inhibitors would be an 
important next step for these agents. Potential limitations of this study are that it was 
designed and conducted with cetuximab before data with the fully humanized antibody 
necitumumab were available that recognized that EGFR monoclonal antibodies are likely 
best directed against SC lung cancer.
In conclusion, there was no significant benefit in adding cetuximab to platinum-based 
chemotherapy with or without bevacizumab in patients with EGFR-FISH+ cancers or in the 
unselected intent-to-treat patient population. The trend observed in the subset of patients 
with EGFR-FISH+ SC carcinoma, though interesting, highlights the need to further 
characterize subpopulations of patients who may benefit from EGFR inhibitor therapies in 
the chemotherapy-naïve advanced NSCLC setting.
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Research in Context
Evidence before this study
The treatment of NSCLC has changed significantly in recent years. While many patients 
benefit from targeted therapy and/or immunotherapy there remain a large number who 
receive chemotherapy in the frontline setting. Improving upon this is of critical 
importance and targeting EGFR is one such approach. We searched PubMed for clinical 
trials published in English from January 1, 2007 to July 30, 2017 using the terms “lung 
cancer and EGFR”; 515 results were retrieved. Of these, several published after the 
beginning of our trial accrual were of particular relevance. The Phase II Lung Cancer 
Cetuximab Study and the Phase III FLEX study demonstrated the benefit of using EGFR 
antibodies plus chemotherapy over chemotherapy alone in patients with EGFR-positive 
advanced NSCLC. Subsequent analyses of FLEX revealed the utility of EGFR expression 
level as a biomarker for survival benefit with cetuximab. Another such biomarker, EGFR 
FISH-positivity, has shown predictive potential in several prior clinical trials, thus 
warranting further analysis in larger patient populations. Most recently, these findings 
have been reinforced by the results of the SQUIRE trial of the anti-EGFR antibody 
necitumumab plus chemotherapy in patients with EGFR-expressing tumors. However, 
analyses from other studies of cetuximab plus chemotherapy produced conflicting results, 
finding no correlation between EGFR expression and outcome. Our study sought to 
determine the role of EGFR FISH-positivity to predict the efficacy of anti-EGFR 
antibody therapy with cetuximab in combination with chemotherapy.
Added value of this study
The current Phase III trial is the largest biomarker validation study to date designed to 
assess the ability of EGFR FISH-positivity to predict outcomes to first-line cetuximab 
treatment in combination with platinum-based doublet chemotherapy, with or without 
bevacizumab. The co-primary objectives comparing PFS in EGFR-FISH+ patients and 
OS in the entire study population were not significantly different between cetuximab and 
non-cetuximab treatment arms. Among secondary objectives, there were no significant 
differences in OS or PFS between cetuximab and non-cetuximab treatment arms with or 
without bevacizumab treatment and stratified by EGFR FISH-positivity. Though EGFR 
FISH-positivity was not predictive in the overall NSCLC patient population, patients with 
SC histology who were EGFR-FISH+ experienced longer OS (P = 0·01) with cetuximab 
treatment than those patients who did not receive cetuximab.
Implications of all the available evidence
Cetuximab added to carboplatin and paclitaxel, with or without bevacizumab, did not 
significantly extend OS in the overall study population or PFS in the patients with EGFR-
FISH+ cancers. The findings of this study, in addition to recent data from the SQUIRE 
trial, suggest that the biology of SC NSCLC may be fundamentally different from that of 
non-squamous NSCLC in its responsiveness to EGFR inhibition.
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Figure 1. 
CONSORT diagram.
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Figure 2. 
Co-primary endpoints, a) PFS in patients with EGFR-FISH+ cancers; b) OS in the entire 
study population
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Figure 3. 
Forest plots for PFS (a) and OS (b) HRs
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Table 1
Baseline Patient Demographics and Characteristics
EGFR FISH+ Patients All Patients
% (n) Control
(n=201)
+ Cetuximab
(n=199)
Control
(n=657)
+ Cetuximab
(n=656)
Age (median, range) 64 (34 – 84) 62 (37 – 80) 63 (30 – 86) 63 (19 – 84)
 >65 years 94 (47) 78 (39) 278 (42) 275 (42)
Sex
 Male 57 (115) 63 (125) 55 (359) 59 (385)
 Female 43 (86) 37 (74) 45 (298) 41 (271)
M-stage
 M1a 27 (54) 22 (43) 45 (297) 45 (292)
 M1b 73 (147) 78 (156) 46 (303) 46 (305)
Bevacizumab treatment
 Bevacizumab 40 (80) 44 (87) 42 (277) 43 (283)
 No Bevacizumab 60 (121) 56 (112) 58 (380) 57 (373)
Smoking History
 Current 44 (89) 47 (94) 45 (297) 45 (292)
 Former 47 (94) 44 (87) 46 (303) 46 (305)
 Never 9 (18) 9 (18) 9 (57) 9 (59)
Histology
 SC 28 (56) 28 (55) 25 (161) 24 (160)
 Adenocarcinoma 60 (120) 65 (130) 62 (408) 63 (411)
 Other* 12 (25) 7 (14) 13 (88) 13 (85)
Performance Status**
0 32 (64) 41 (81) 35 (229) 39 (256)
1 68 (137) 59 (118) 65 (427) 61 (400)
EGFR FISH Status†
 EGFR-FISH+ 201 (100%) 199 (100%) 31 (201) 30 (199)
 EGFR FISH-negative     –     – 45 (293) 43 (283)
 EGFR FISH-unknown     –     – 25 (163) 27 (174)
*
Includes large cell, BAC, mixed, other, and not reported;
**
One patient on the Control arm was missing documentation.
†
In the control and cetuximab arms, EGFR FISH analysis failed in 4% and 5% of patients, there was inadequate specimen in 12% and 11% of 
cases, and there were no data in 9% and 10% of cases, respectively.
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Table 3
Response rates in subset of patients with measureable disease (per RECIST) at baseline
Analysis Group Outcome All Patients EGFR FISH-Positive EGFR FISH Non-Positive
All Patients Cetuximab Arm RR, 
95% CI
257/617 = 42% (38% – 
46%)
87/187 = 47% (39% – 54%) 170/430 = 40% (35% – 44%)
Control Arm RR, 
95% CI
227/623 = 36% (33% – 
40%)
82/191 = 43% (36% – 50%) 145/432 = 34% (29% – 38%)
p-value   0.06   0.48   0.07
Bevacizumab Cetuximab Arm RR, 
95% CI
126/266 = 47% (41% – 
53%)
44/83 = 53% (42% – 64%) 82/183 = 45% (38% – 52%)
Control Arm RR, 
95% CI
118/255 = 46% (40% – 
52%)
46/75 = 61% (50% – 72%) 72/180 = 40% (33% – 47%)
p-value   0.80   0.29   0.35
No Bevacizumab Cetuximab Arm RR, 
95% CI
131/351 = 37% (32% – 
42%)
43/104 = 41% (32% – 51%) 88/247 = 36% (30% – 42%)
Control Arm RR, 
95% CI
109/368 = 30% (25% – 
34%)
36/116 = 31% (23% – 39%) 73/252 = 29% (23% – 35%)
p-value   0.03   0.11   0.11
Squamous Cell Histology Cetuximab Arm RR, 
95% CI
59/150 = 39% (32% – 
47%)
23/50 = 46% (32% – 60%) 36/100 = 36% (27% – 45%)
Control Arm RR, 
95% CI
54/155 = 35% (27% – 
42%)
21/54 = 39% (26% – 52%) 33/101 = 33% (24% – 42%)
p-value   0.42   0.46   0.62
Non-Squamous Histology Cetuximab Arm RR, 
95% CI
198/467 = 42% (38% – 
47%)
64/137 = 47% (38% – 55%) 134/330 = 41% (35% – 46%)
Control Arm RR, 
95% CI
173/468 = 37% (33% – 
41%)
61/137 = 45% (36% – 53%) 112/331 = 34% (29% – 39%)
p-value   0.09   0.72   0.07
Footnote: RR = Response rate; CI = Confidence Interval
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